Trial Profile
A Prospective, One-arm Open Clinical Trial of Apatinib Combined With Albumin Paclitaxel and Carboplatin as a Neoadjuvant Therapy for the Safety and Efficacy of Triple-negative Breast Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Aug 2020
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Rivoceranib (Primary)
- Indications Advanced breast cancer; Early breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 06 Aug 2020 According to ClinicalTrials.gov: US National Institutes of Health, status of the trial is unknown as the information has not been verified recently(Last verified;Aug 2018).
- 06 Sep 2018 New trial record